{"name":"Barrie Urology Associates","slug":"barrie-urology-associates","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Oxycodone and acetaminophen combination treatment","genericName":"Oxycodone and acetaminophen combination treatment","slug":"oxycodone-and-acetaminophen-combination-treatment","indication":"Moderate to severe acute pain","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Solifenacin succinate treatment","genericName":"Solifenacin succinate treatment","slug":"solifenacin-succinate-treatment","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency","status":"marketed"}]}],"pipeline":[{"name":"Oxycodone and acetaminophen combination treatment","genericName":"Oxycodone and acetaminophen combination treatment","slug":"oxycodone-and-acetaminophen-combination-treatment","phase":"marketed","mechanism":"Oxycodone binds to opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.","indications":["Moderate to severe acute pain","Post-operative pain management"],"catalyst":""},{"name":"Solifenacin succinate treatment","genericName":"Solifenacin succinate treatment","slug":"solifenacin-succinate-treatment","phase":"marketed","mechanism":"Solifenacin succinate is a muscarinic M3 receptor antagonist that reduces involuntary bladder muscle contractions.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and frequency"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}